Telesis Bio Dividendos y recompras

Dividendo controles de criterios 0/6

Telesis Bio no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

-2.2%

Rendimiento de la recompra

Rendimiento total para el accionista	-2.2%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Apr 17

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Aug 09

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 25

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

Jan 06

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Sep 24

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de TBIO han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de TBIO han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Telesis Bio vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de TBIO con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (TBIO)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.2%
Media de la industria (Life Sciences)	0.5%
Analista de previsiones (TBIO) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de TBIO en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de TBIO en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de TBIO para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que TBIO no ha comunicado ningún pago.

Telesis Bio Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Yuan (Terry) Yang entered into an agreement to acquire Eton Bioscience, Inc. from Telesis Bio, Inc. (NasdaqGS:TBIO) for $1.5 million

Telesis Bio Receives Non-Compliance Letter from Nasdaq

Telesis Bio Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Announces Chief Executive Officer Changes

Telesis Bio, Inc., Annual General Meeting, May 01, 2024

Telesis Bio, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Telesis Bio Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Provides Earnings Guidance for 2023

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Telesis Bio, Inc. Announces Board Changes

Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations

Telesis Bio, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Telesis Bio, Inc. Appoints Paul Meister as Director

Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor

Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm

Telesis Bio, Inc., Annual General Meeting, Jul 06, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Forecast to breakeven in 2025

Consensus estimates of losses per share improve by 17%

Forecast to breakeven in 2025

Telesis Bio Releases BioXp Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Telesis Bio Provides Revenue Guidance for the Fourth Quarter of 2022

President recently bought US$192k worth of stock

Price target decreased to US$6.50

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Telesis Bio, Inc. Revises Revenue Guidance for the Full Year 2022

Telesis Bio, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Codex DNA, Inc. Announces Resignation of Brent Hunter as Vice President, Finance

Codex DNA, Inc. Expands Application of Proprietary Error Correction Technology

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

Codex Dna Debuts Next-Generation Automated Synthetic Biology Workstation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Codex DNA, Inc. Raises Revenue Guidance for the Full Year of 2022

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Codex DNA, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Codex DNA, Inc. Appoints Annette Tumolo to Serve as A Class III Director

Codex DNA, Inc.(NasdaqGS:DNAY) dropped from Russell 2500 Value Index

Codex DNA, Inc. Appoints Eric Esser to Serve as the Chief Operating Officer

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Codex DNA, Inc. to Report Q1, 2022 Results on May 10, 2022

Codex DNA, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Codex Dna, Inc. Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development At World Vaccine Congress Washington 2022

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Codex DNA, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Codex DNA, Inc. Showcases Potential of SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

High number of new and inexperienced directors

Codex DNA, Inc. Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant

Codex DNA, Inc. Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System

Third quarter 2021 earnings released: US$0.34 loss per share

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Senior Vice President of Commercial Operations Timothy Cloutier has left the company

Codex DNA, Inc. has completed an IPO in the amount of $106.66664 million.

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos